Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

UroGen Pharma (URGN) Debt to Equity (2022 - 2025)

UroGen Pharma (URGN) has disclosed Debt to Equity for 4 consecutive years, with -$1.16 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Debt to Equity rose 91.62% year-over-year to -$1.16, compared with a TTM value of -$1.16 through Dec 2025, up 91.62%, and an annual FY2025 reading of -$1.16, up 91.62% over the prior year.
  • Debt to Equity was -$1.16 for Q4 2025 at UroGen Pharma, down from -$1.06 in the prior quarter.
  • Across five years, Debt to Equity topped out at $4.77 in Q3 2024 and bottomed at -$13.83 in Q4 2024.
  • Average Debt to Equity over 4 years is -$1.75, with a median of -$1.24 recorded in 2025.
  • Peak annual rise in Debt to Equity hit 554.42% in 2024, while the deepest fall reached 815.06% in 2024.
  • Year by year, Debt to Equity stood at -$1.09 in 2022, then crashed by 38.46% to -$1.51 in 2023, then plummeted by 815.06% to -$13.83 in 2024, then soared by 91.62% to -$1.16 in 2025.
  • Business Quant data shows Debt to Equity for URGN at -$1.16 in Q4 2025, -$1.06 in Q3 2025, and -$1.31 in Q2 2025.